Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Loncastuximab tesirine 150 µg/Kg · 1 trial · 1 indication
CR rate is defined as the Complete Response (CR)/n, where n is the number of participants. The proportion of patients with best overall response of complete response (CR), per Cheson criteria if disease is not PET (Positron emission tomography)-avid in initial screening and by revised Lugano criteria if screening PET-CT demonstrated PET-avid disease.CR will be defined by a Deauville score of ≤ 3.
CR rate is defined as the Complete Response (CR)/n, where n is the number of participants. The proportion of patients with best overall response of complete response (CR), per Cheson criteria if disease is not PET-avid in initial screening and by revised Lugano criteria if screening PET-CT demonstrated PET-avid disease.CR will be defined by a Deauville score of ≤ 3.
| Arm | Type | Description |
|---|---|---|
| Loncastuximab tesirine Cycles 1-6 | EXPERIMENTAL | Patients will be treated with loncastuximab tesirine for a total of 6 cycles on Day 1 (+/-3) of each 21 day (3 week) cycle. The total duration of treatment is approximately 18 weeks (4.5 months) |
| Name | Type | Description |
|---|---|---|
| Loncastuximab tesirine 150 µg/Kg | DRUG | Participants will be treated with loncastuximab tesirine at a dose of 150 µg/Kg given as an intravenous infusion (given as per treatment guidelines for 30 minutes or longer) on Day 1 (+/- 3 days) of each 21 day cycle for Cycle 1 - 2. |
| Loncastuximab tesirine 75µg/Kg | DRUG | Participants will be treated with loncastuximab tesirine at a dose of 75 µg/Kg given as an intravenous infusion (given as per treatment guidelines for 30 minutes or longer) on Day 1 (+/- 3 days) of each 21 day cycle for Cycle 3 - 6. |
Inclusion Criteria: 1. Men and women, aged 18 years or older. 2. Histologically confirmed MZL, including extranodal, nodal, and splenic subtypes. 3. Previously received 1 or more lines of systemic therapy, including at least 1 anti-CD20 antibody (cluster of differentiation antigen 20) (either as mo...
Loncastuximab tesirine 150 µg/Kg is an investigational oncology drug being studied for the treatment of Marginal Zone Lymphoma, a type of non-Hodgkin lymphoma. It is currently in Phase 2 clinical development for this indication.
Loncastuximab tesirine 150 µg/Kg is an antibody-drug conjugate that targets CD19, a protein expressed on B-cells. It delivers a cytotoxic payload to CD19-positive cells, which is relevant for treating B-cell malignancies like Marginal Zone Lymphoma.
Loncastuximab tesirine 150 µg/Kg is being developed by ADC Therapeutics SA, a biopharmaceutical company focused on oncology. The company's stock is traded under the ticker ADCT.
Loncastuximab tesirine 150 µg/Kg is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities for any use.
Loncastuximab tesirine 150 µg/Kg is being evaluated in a Phase 2 clinical trial with the identifier NCT05296070. This open-label, uncontrolled study is recruiting patients with relapsed or refractory Marginal Zone Lymphoma in the United States.
Yes, Loncastuximab tesirine 150 µg/Kg is also known as ADCT-402. The clinical trial NCT05296070 refers to the drug as ADCT-402, and it is being studied in patients with Marginal Zone Lymphoma.